Thus, the simpler DRhQ construct was designed, retaining just the conserved-in-human DRα1 domain (without the polymorphic HLA-DRβ1 domain) linked to the MOG-35-55 peptide extension, with the added benefit that it can be administered to all recipients without need for tissue type matching.